Ozempic competitor: New weight-loss drug expected to get FDA approval in coming months could be even more powerful than Wegovy

People who are overweight are flocking to the drug Ozempic to slim down. Looming is an even more powerful weight-loss treatment.

The drug Mounjaro helped a typical person with obesity who weighed 230 pounds lose up to 50 pounds during a test period of nearly 17 months.

The advance of Mounjaro, which is already on the market to treat Type 2 diabetes, has excited doctors and patients who have been waiting decades for effective treatments, while helping turn its maker, Eli Lilly & Co., into the most valuable standalone pharmaceutical company in the U.S. with a market value of more than $300 billion.

Related on the SLP

No related posts.

Astrology, homeopathy, vaccine rejectionism, creationism: Why pseudoscience thrives as science advances

Viewpoint: After firing the entire National Science Board, Trump reshapes funding initiatives. Here’s the good and the bad.

Energy-sucking data centers are unpopular across the political spectrum. Could moving them into space change the equation?

In May 2022, the FDA approved Mounjaro for the treatment of Type 2 diabetes. Lilly expects to complete the application for Mounjaro’s use treating obesity after results of another study are available by the end of April, which could lead to approval later this year or early 2024.